« Return to News | Awards & Advancement

Naurex completes $18 Million Series A

Wednesday, May 11, 2011 12:59 PM

Naurex, a clinical-stage company developing innovative treatments to address unmet needs in psychiatry and neurology, has completed an $18 million Series A financing led by Adams Street Partners and Latterell Venture Partners. 

Naurex will use the proceeds from the Series A financing primarily for the phase II trial of its lead compound, GLYX-13, a glycine-site functional partial agonist (GFPA) selective modulator of the NMDA receptor (NMDAR), and also to advance its second-generation GFPA program. 

Naurex will also appoint Wilbur (Bill) Gantz of PathoCapital as chairman of Naurex's board of directors, a newly created position.  Previously, he was executive chairman of Ovation Pharmaceuticals.  Terry Gould of Adams Street Partners and Kenneth Widder, M.D., of Latterell Ventures are also joining as directors. 

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.